Abstract: Disclosed are cell lines that stably express CRISPR SAM complex which comprise a gRNA that specifically targets a promoter of a gene, wherein the gene is not normally expressed in said cell. Also disclosed are methods of measuring the ability of a vector to transfer a nucleic acid molecule into such cell lines.
Type:
Application
Filed:
December 2, 2021
Publication date:
January 4, 2024
Applicant:
Decibel Therapeutics, Inc.
Inventors:
Meghan DRUMMOND SAMUELSON, Leah SABIN, Sarah CANCELARICH
Abstract: Hypertonic pharmaceutical compositions are disclosed. The hypertonic pharmaceutical compositions contain an anti-platinum chemoprotectant agent and a gelling agent. Also disclosed are methods of medical use of the hypertonic pharmaceutical compositions.
Abstract: Disclosed herein are methods for otoprotection against platinum-based antineoplastic agents by administering a thiosulfate salt to a subject in need thereof. Typically, the thiosulfate salt is administered to the subject scheduled to be administered a platinum-based antineoplastic agent within 4 hours. Alternatively, the thiosulfate salt is administered within 7 hours after the administration of a platinum-based neoplastic agent.
Type:
Grant
Filed:
October 26, 2020
Date of Patent:
July 4, 2023
Assignee:
Decibel Therapeutics, Inc.
Inventors:
John Lee, John R. Soglia, Qi-Ying Hu, Fuxin Shi
Abstract: The disclosure features compositions and methods for the treatment of sensorineural hearing loss and auditory neuropathy, particularly forms of the disease that are associated with mutations in otoferlin (OTOF), by way of OTOF gene therapy. The disclosure provides a variety of compositions that include a first nucleic acid vector that contains a polynucleotide encoding an N-terminal portion of an OTOF protein and a second nucleic acid vector that contains a polynucleotide encoding a C-terminal portion of an OTOF protein. These vectors can be used to increase the expression of OTOF in a subject, such as a human subject suffering from sensorineural hearing loss.
Type:
Grant
Filed:
April 26, 2019
Date of Patent:
May 30, 2023
Assignee:
Decibel Therapeutics, Inc.
Inventors:
Joseph Burns, Kathryn Ellis, Adam Palermo, Martin Schwander, Jonathon Whitton
Abstract: This disclosure relates to methods for expanding inner ear supporting cells (e.g., Lgr5+ inner ear supporting cells) and differentiating inner ear supporting cells (e.g., Lgr5+ inner ear supporting cells) to inner ear hair cells (e.g., atonal homolog 1 (Atoh1)+ inner ear hair cells) and the use of the inner hear supporting cells and hair cells, e.g., for identifying candidate therapeutic compounds for the treatment of hearing loss and balance loss. Additionally, the methods described herein can be used in the treatment of a subject having hearing loss and balance loss that would benefit from increased proliferation and differentiation of inner ear supporting cells (e.g., Lgr5+ inner ear supporting cells).
Type:
Grant
Filed:
January 27, 2017
Date of Patent:
October 11, 2022
Assignees:
Massachusetts Eye and Ear Infirmary, Decibel Therapeutics, Inc.
Inventors:
Albert Edge, Michael Venuti, Agnieszka Czechowicz
Abstract: Hypertonic pharmaceutical compositions are disclosed. The hypertonic pharmaceutical compositions contain an anti-platinum chemoprotectant agent and a gelling agent. Also disclosed are methods of medical use of the hypertonic pharmaceutical compositions.
Abstract: Disclosed herein are methods for otoprotection against platinum-based antineoplastic agents by administering a thiosulfate salt to a subject in need thereof. Typically, the thiosulfate salt is administered to the subject scheduled to be administered a platinum-based antineoplastic agent within 4 hours. Alternatively, the thiosulfate salt is administered within 7 hours after the administration of a platinum-based neoplastic agent.
Type:
Grant
Filed:
May 31, 2019
Date of Patent:
October 27, 2020
Assignee:
Decibel Therapeutics, Inc.
Inventors:
John Lee, John R. Soglia, Qi-Ying Hu, Fuxin Shi
Abstract: Hypertonic pharmaceutical compositions are disclosed. The hypertonic pharmaceutical compositions contain an anti-platinum chemoprotectant agent and a gelling agent. Also disclosed are methods of medical use of the hypertonic pharmaceutical compositions.